secwatch.observer — SEC 8-K summary
======================================

Issuer:     Summit Therapeutics Inc. (SMMT)
CIK:        0001599298
Form:       8-K
Filed at:   2026-01-29T23:59:59+00:00
Accession:  0001599298-26-000006
Event type: regulatory
Sentiment:  positive
Materiality: 0.75
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Summit Therapeutics BLA for ivonescimab in EGFR-mutated NSCLC accepted by FDA; PDUFA Nov 14, 2026
--------------------------------------------------------------------------------

- FDA accepted BLA for ivonescimab + chemotherapy in EGFR-mutated non-squamous NSCLC post-TKI therapy.
- PDUFA goal action date set for November 14, 2026.
- BLA submission based on Phase III HARMONi trial results.
- Over 14,000 U.S. patients eligible for treatment annually in this setting.
- FDA plans full review including mid-cycle and wrap-up meetings before PDUFA date.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1599298/000159929826000006/0001599298-26-000006-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1599298/000159929826000006/smmt-20260129.htm
  HTML page:      https://secwatch.observer/filing/0001599298-26-000006

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer